Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 20/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26326400 | 1.00 | XPO1 (0.64) | XPO1 | |
| SCHEMBL12128273 | 0.93 | XPO1 (0.59) | XPO1 | |
| SCHEMBL18051388 | 0.92 | XPO1 (0.65) | XPO1 | |
| SCHEMBL15195259 | 0.91 | XPO1 (0.57) | XPO1 | |
| SCHEMBL12127023 | 0.91 | XPO1 (0.74) | XPO1 | |
| SCHEMBL12127021 | 0.91 | XPO1 (0.63) | XPO1 | |
| SCHEMBL12128219 | 0.90 | XPO1 (0.56) | XPO1 | |
| SCHEMBL12128200 | 0.89 | XPO1 (0.56) | XPO1 | |
| SCHEMBL12128138 | 0.89 | XPO1 (0.75) | XPO1 | |
| SCHEMBL12128278 | 0.89 | XPO1 (0.78) | XPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787771-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20180127384-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2018-05-10 | — | — | US | disclosed |
| US-9714226-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160304472-A1 | Hydrazide Containing Nuclear Transport Modulators and Uses Thereof | Karyopharm Therapeutics Inc. | 2016-10-20 | — | — | US | disclosed |
| US-9206158-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150274698-A1 | Hydrazide Containing Nuclear Transport Modulators And Uses Thereof | Karyopharm Therapeutics Inc. | 2015-10-01 | — | — | US | disclosed |
| US-9079865-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2015-07-14 | — | — | US | disclosed |
| US-8999996-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140364408-A1 | Hydrazide Containing Nuclear Transport Modulators And Uses Thereof | Karyopharm Therapeutics Inc. (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304472-A1 | Hydrazide Containing Nuclear Transport Modulators and Uses Thereof | XPO1, KPNA1, ABCB11 | XPO1 1/4885 |
| US-20150274698-A1 | Hydrazide Containing Nuclear Transport Modulators And Uses Thereof | XPO1, KPNA1, ABCB11 | XPO1 1/4885 |
| US-11787771-B2 | Hydrazide containing nuclear transport modulators and uses thereof | XPO1, KPNA1, ABCB11 | XPO1 1/4885 |
| US-20140364408-A1 | Hydrazide Containing Nuclear Transport Modulators And Uses Thereof | ABCB11, XPO1, KPNA1 | XPO1 2/4885 |
| US-20180127384-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, KPNA1, ABCB11 | XPO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.